Anticarbohydrate antibodies in patients with inflammatory bowel disease

ABSTRACT

Evaluating the prevalence of antichitobioside carbohydrate antibody [ACCA], antilaminaribioside carbohydrate antibodies [ALCA], antimannobioside carbohydrate antibodies [AMCA] and anti-Saccharomyces cerevisiae antibodies [ASCA], in patients with inflammatory bowel disease [IBD]. 268 serum samples were used; 115 Crohn's disease [CD], 83 ulcerative colitis, and 70 healthy control samples. All samples were evaluated using enzyme-linked immunosorbent assay for the following four anticarbohydrate antibodies ACCA, ALCA, AMCA, and ASCA. In patients with Crohn's disease the prevalence of the anticarbohydrate antibodies was ASCA 69%, AMCA 32%, ACCA 28% and ALCA 24% with the highest prevalence being for ASCA [P-value<0.0001] while in patients with ulcerative colitis the prevalence was ACCA 46%, AMCA 35%, ALCA 23% and ASCA 15% with the highest prevalence being for ACCA [P-value 0.00l]. Anticarbohydrate antibodies are significantly present in patients with IBD. The use of a panel of anticarbohydrate antibodies may provide additional help in distinguishing IBD from non-IBD disease patterns and narrow the range of differential diagnosis in these patients